Phaseline

Targets › MTM1

MTM1 (Myotubularin): drug programs, companies and trials

2 programs from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Neurology; next expected readout Oct 2027.

Lipid phosphatase which dephosphorylates phosphatidylinositol 3-monophosphate (PI3P) and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). Has also been shown to dephosphorylate phosphotyrosine- and phosphoserine-containing peptides. (UniProt, Q13496)

Open in Phaseline: the race on MTM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstellasResamirigene bilparvovec (AT132)
AAV8 vector containing a functional copy of the human MTM1 gene
MTM1Phase 2X-Linked Myotubular MyopathyMar 2030
AstellasASP2957
AAV gene therapy delivering MTM1 gene with MHCK7 promoter and MyoAAV3.8 engineered capsid
MTM1Phase 1X-Linked Myotubular MyopathyOct 2027

Conditions

X-Linked Myotubular Myopathy (2)

Modalities

mixed (1), other (1)

Companies

Astellas (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.